-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 13, Pfizer announced that it had reached a definitive agreement with Arena to acquire all of the latter’s outstanding shares in cash at a price of US$100 per share, with a total transaction value of approximately US$6.
7 billion
.
The board of directors of both companies unanimously agreed on this transaction
Arena's pipeline products are mainly concentrated in the fields of gastrointestinal diseases, skin diseases and heart diseases
.
Including an oral selective sphingosine 1-phosphate (S1P) receptor modulator etrasimod, which has been developed to treat a series of immune inflammatory diseases including gastrointestinal and skin diseases
Etrasimod is currently conducting two phase III studies for ulcerative enteritis, one phase II/III study for Crohn's disease, one phase III study for atopic dermatitis, and phase II studies for eosinophilic esophagitis and alopecia areata
.
On December 5, 2017, Genting Shining won the exclusive development and commercialization rights of etrasimod and ralinepag in Greater China from Arena, with a down payment of 12 million U.
Arena’s research pipeline also includes two phase II cardiovascular drugs, temanogrel and APD418
.
Temanogrel was developed to treat microvascular obstruction secondary to systemic sclerosis and Raynaud's syndrome, and APD418 was developed to treat acute heart failure
Original link: https://
https://